Richard Sposto

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3702346/richard-sposto-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18 1,021 47 31 h-index g-index citations papers 3.96 49 1,239 4.7 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
47	Independent Assessment of the Children@ Hepatic Tumors International Collaboration Risk Stratification for Hepatoblastoma and the Association of Tumor Histological Characteristics With Prognosis <i>JAMA Network Open</i> , 2022 , 5, e2148013	10.4	1
46	Surveillance for radiation-related late effects in childhood cancer survivors: The impact of using volumetric dosimetry. <i>Cancer Medicine</i> , 2021 , 10, 905-913	4.8	1
45	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. <i>Clinical Cancer Research</i> , 2020 , 26, 2297-2307	12.9	12
44	Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2020 , 34, 2473-2478	10.7	16
43	mRNA and miRNA Profiles of Exosomes from Cultured Tumor Cells Reveal Biomarkers Specific for HPV16-Positive and HPV16-Negative Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
42	Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controls. Haematologica, 2020 , 105, 83-90	6.6	20
41	Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. <i>Pharmaceutical Statistics</i> , 2019 , 18, 659-670	1	2
40	Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial. <i>Clinical Trials</i> , 2019 , 16, 599-609	2.2	1
39	Rejoinder. <i>Clinical Trials</i> , 2019 , 16, 613-615	2.2	
38	Clinical findings and outcomes of MRI staging of breast cancer in a diverse population. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 315-324	4.4	2
37	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2019 , 33, 884-892	10.7	119
36	Dose Sculpting Intensity Modulated Radiation Therapy for Vertebral Body Sparing in Children With Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 550-557	4	7
35	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. <i>Leukemia</i> , 2018 , 32, 2316-2325	10.7	60
34	Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children. <i>Blood</i> , 2018 , 132, 139-139	2.2	2
33	Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. <i>Cell Reports</i> , 2018 , 25, 2177-2191.e7	10.6	51
32	Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" I and II clinical trials. <i>Journal of Neuro-Oncology</i> , 2018 , 140, 717-725	4.8	4
31	A novel cross-correlation methodology for assessing biophysical responses associated with pain. Journal of Pain Research, 2018 , 11, 2207-2219	2.9	3

(2014-2017)

30	Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study. <i>Biology of Blood</i>	4.7	5
29	Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain. American Journal of Hematology, 2017, 92, 1137-1145	7.1	22
28	Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting. <i>Pediatric Hematology and Oncology</i> , 2017 , 34, 349-354	1.7	2
27	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. <i>Clinical Cancer Research</i> , 2016 , 22, 4014-22	12.9	43
26	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2016 , 18, 126-31	1	44
25	Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. <i>Blood</i> , 2016 , 128, 2781-2	2 7 81	5
24	Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children@Oncology Group. <i>Cancer</i> , 2016 , 122, 1928-36	6.4	67
23	Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response. <i>Gynecologic Oncology</i> , 2016 , 143, 650-654	4.9	7
22	The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1064-72	4	19
21	Validation of self-reported comorbidity status of breast cancer patients with medical records: the California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Causes and Control</i> , 2016 , 27, 391-407	1 ^{2.8}	12
20	Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. <i>Journal of Community Health</i> , 2015 , 40, 1287-99	4	40
19	Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 361	-8	53
18	Contribution of the neighborhood environment and obesity to breast cancer survival: the California Breast Cancer Survivorship Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1282	- 9 0	25
17	Tumor-associated macrophages in SHH subgroup of medulloblastomas. <i>Clinical Cancer Research</i> , 2015 , 21, 1457-65	12.9	68
16	Escalation of oncologic services at the end of life among patients with gynecologic cancer at an urban, public hospital. <i>Journal of Oncology Practice</i> , 2015 , 11, e163-9	3.1	13
15	Thromboelastography to Detect Hypercoagulability in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1118-1118	2.2	2
14	Comparison of Vincristine Pharmacokinetics (PK) in Adolescent/Young Adult (AYA) Versus Younger Patients Defined By Tanner Stage during Treatment for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015 , 126, 3725-3725	2.2	2
13	Molecular and clinical diagnosis of group A streptococcal pharyngitis in children. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3884-9	9.7	25

12	Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2014 , 124, 3932-8	2.2	53
11	MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. <i>Cancer Research</i> , 2014 , 74, 5999-6009	10.1	8
10	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2014 , 124, 795-795	2.2	16
9	Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to	2.2	
8	Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation (AuHCT) in pediatric patients with malignant brain tumors <i>Journal of Clinical Oncology</i> , 2013 , 31, 2049-	2049	
7	A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs. <i>Contemporary Clinical Trials</i> , 2011 , 32, 694-703	2.3	10
6	Commentary on paper, Q ancer survival analysisQ <i>Surgical Oncology</i> , 2010 , 19, 59-60; discussion 61	2.5	2
5	An adjustment for patient heterogeneity in the design of two-stage phase II trials. <i>Statistics in Medicine</i> , 2009 , 28, 2566-79	2.3	9
4	Cure model analysis in cancer: an application to data from the Children@ Cancer Group. <i>Statistics in Medicine</i> , 2002 , 21, 293-312	2.3	89
3	Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children@ Cancer Group. <i>Medical and Pediatric Oncology</i> , 2001 , 37, 432-41		37
2	A strategic view of randomized trial design in low-incidence paediatric cancer. <i>Statistics in Medicine</i> , 1999 , 18, 1183-97	2.3	12
1	Use of unequal allocation in survival trials. <i>Statistics in Medicine</i> , 1987 , 6, 119-25	2.3	20